Outlook Therapeutics Inc. Common Stock (OTLK)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach clinical-stage biotechnology with Graham's caution: without earnings or assets, I am underwriting a probability, not a business. Outlook Therapeutics has 17 employees and is developing ONS-5010, an ophthalmic formulation of bevacizumab, still in Phase III. In fiscal 2025, the year ended 2025-09-30, it reported revenue of $1.4 million and a net loss of $62.4 million, or $1.79 per diluted share. Fiscal 2024 showed no revenue and a $75.4 million net loss, or $4.06 per share; fiscal 2023 no revenue and a $59.0 million loss, or $4.72 per share. More recently, in fiscal Q3 2026, the quarter ended 2026-06-30, revenue was not available in the filed figures and net loss was $20.3 million, or $0.15 per diluted share. Those are not the marks of a self-funding enterprise.

In plain English: Outlook Therapeutics is a small drug developer working on an eye medicine called ONS-5010. It has no steady revenue and has lost money in each of the last four years. At $0.56 a share, the price looks low, but because there are no profits, it is hard to call it cheap or expensive from the business numbers alone.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2023 10-K (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer